VasGene is a clinical-stage company dedicated to the development and commercialization of innovative therapeutics based on the understanding of vascular biology and cancer biology. Breakthroughs in the basic understanding of the vascular networks and cancer combined with powerful new biotechnological tools have provided the foundation for new, rational, and technologically sophisticated approaches to cancer therapeutics.
VasGene’s products target signal transduction pathways common to tumor cells and endothelial cells, resulting in powerful anti-cancer agents with multiple modes of action: induction of tumor cell apaptosis, inhibition of tumor angiogenesis, prevention of tumor cell metastasis and recruitment of immune system to the spot of action.
VasGene has developed an extensive and well-protected intellectual property portfolio covering various therapeutic targets.
VasGene has also acquired an extensive and well-protected intellectual property portfolio based on key licensing agreements with the University of Southern California and California Institute of Technology.
Privately held, VasGene is headquartered in Los Angeles, CA.
© 2015 VasGene Therapeutics, Inc. | All rights reserved